Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 3/2020

01-07-2020 | Anemia | Short Communication

Hematopoietic Stem Cell Transplantation for Fanconi Anemia: A Single Center Experience from India

Authors: Divya Doval, Dharma Choudhary, Sanjeev Kumar Sharma, Vipin Khandelwal, Meet Kumar, Anil Handoo, Rasika Setia

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 3/2020

Login to get access

Abstract

Hematopoietic stem cell transplantation (HSCT) is the only treatment option for the hematological manifestations of Fanconi anemia (FA). Fludarabine based reduced intensity conditioning regimens have helped in improving outcomes significantly in FA patients. We retrospectively analyzed the outcomes of FA patients who underwent allogeneic HSCT at BLK Superspeciality Hospital, New Delhi from June 2011 to September 2019. Twenty FA patients underwent 23 transplants at our center. Overall survival and disease free survival were 65% and 50%, respectively at a median of 23 months. Overall mortality was 30%. HSCT for FA is a feasible option even in developing countries although children present late to transplant centers after multiple transfusions and infections.
Literature
1.
2.
Wagner JE, Eapen M, MacMillan ML et al (2007) Unrelated donor bone marrow transplantation for the treatment of Fanconi anaemia. Blood 10:2256–2262CrossRef
3.
MacMillan ML, Wagner JE (2010) Haematopoeitic cell transplantation for Fanconi anaemia—When and how? Br J Haematol 149:14–21PubMedCrossRef
4.
de Latour RP, Porcher R et al (2013) Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the EBMT experience. Blood 01:479733
5.
Benajiba L, Salvado C, Dalle JH et al (2015) HLA-matched related-donor HSCT in Fanconi anemia patients conditioned with cyclophosphamide and fludarabine. Blood 125(2):417–418PubMedCrossRef
6.
Smetsers SE, Smiers FJ et al (2016) Four decades of stem cell transplantation for Fanconi anaemia in the Netherlands. Br J Haematol 174:952–961PubMedCrossRef
7.
Locatelli F, Zecca M et al (2007) The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: a report from the Italian pediatric group. Haematologica 92:1381–1388PubMedCrossRef
8.
Ayas M (2017) Hematopoietic cell transplantation in Fanconi anemia and dyskeratosis congenita: a mini review. Hematol Oncol Stem Cell Ther 10:285–289PubMedCrossRef
9.
Ebens CL, MacMillan ML, Wagner JE (2017) Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations. Expert Rev Hematol 10(1):81–97PubMedCrossRef
Metadata
Title
Hematopoietic Stem Cell Transplantation for Fanconi Anemia: A Single Center Experience from India
Authors
Divya Doval
Dharma Choudhary
Sanjeev Kumar Sharma
Vipin Khandelwal
Meet Kumar
Anil Handoo
Rasika Setia
Publication date
01-07-2020
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 3/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01254-3

Other articles of this Issue 3/2020

Indian Journal of Hematology and Blood Transfusion 3/2020 Go to the issue

Original Article

Impact of World Health Organization (WHO) Revised Criteria-2016 on the Diagnosis of Polycythemia Vera

Images

Somatic Hemizygous Y371H CBL Mutation with Loss of Heterozygosity Presenting with BENTA Type Lymphoid Proliferation

Review Article

Re-defining Prognosis of Hematological Malignancies by Dynamic Response Assessment Methods: Lessons Learnt in Chronic Myeloid Leukemia, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma and Multiple Myeloma

Original Article

Kidd Blood Group Genotyping for Thalassemia Patient in Iran

Images

Disseminated Cryptococcosis in a Young Immunocompetent Male

Original Article

Efficacy of Dichlorophenolindophenol (DCIP) as Screening Test for Hb E: Revisited
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits